Advertisement

Chemotherapy for malignant intracranial tumors

  • Paul L. Kornblith
  • Michael Walker
Part of the Cancer Treatment and Research book series (CTAR, volume 36)

Abstract

Advances in neurosurgical techniques have had a dramatic impact on the prognosis of patients suffering from benign intracranial neoplasms. Acoustic Schwannomas which carried a high surgical mortality rate in Cushing’s era are now removed safely and successfully as are pituitary tumors and most meningiomas. The impact of these technical advances on the management of the malignant intracranial tumors, in particular on the glioblastoma multiforme, the most common primary malignant intracranial neoplasm, have been slight. The use of radiotherapy clearly adds to patient survival but is limited in its effectiveness. Thus, there has been a search for adjunctive approaches to the therapy of malignant gliomas which could hopefully begin to improve the management of these patients. The effective use of chemotherapy has been severely limited by the lack of therapeutic agents designed for use in brain tumor patients and by the heterogeneity of the tumor cells and the drug delivery problems which often prevent the agents from reaching the tumor site. Thus, results of chemotherapy to date have been modest at best.

Keywords

Brain Tumor Malignant Glioma Malignant Brain Tumor Brain Tumor Patient Cerebellar Astrocytoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Scanlon PW and Taylor WF: Radiotherapy of intracranial astrocytomas: Analysis of 417 cases treated from 1960 through 1969. Neurosurgery 5:301–308, 1979.PubMedCrossRefGoogle Scholar
  2. 2.
    McKeever PE and Balentine JD: Macrophage migration through the brain parenchyma to the perivascular space following particle ingestion. Am J Pathol 93:153–164, 1978.PubMedGoogle Scholar
  3. 3.
    Gilles FH, Winston K, Fulchiero A, et al: Histologic features and observational variation in cerebellar gliomas in children. JNCI 58:175–181, 1977.PubMedGoogle Scholar
  4. 4.
    Levin VA: A pharmacologic basis for brain tumor chemotherapy. Semin Oncol 2:57–61, 1975.PubMedGoogle Scholar
  5. 5.
    Levin VA, Freeman MA, and Landahl HD: The permeability characteristics of the edematous brain adjacent to intracerebral rat brain tumors. Arch Neurol 32:785–791, 1975.PubMedGoogle Scholar
  6. 6.
    Shapiro WR, Yung WA, Basler GA, et al: Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro. Cancer Treat Rep 65(suppl 2):55–59, 1981.PubMedGoogle Scholar
  7. 7.
    Hoshino T, Wilson CB, Rosenblum MD, et al: Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. J Neurosurg 43:127–135, 1975.PubMedCrossRefGoogle Scholar
  8. 8.
    Hoshino T: Therapeutic implications of brain tumor cell kinetics. In: Modern Concepts in Brain Tumor Therapy: Laboratory and Clinical Investigations. NCI Monograph 46, DHEW, 1977, p 29–36.Google Scholar
  9. 9.
    Rail DP and Zubrod CG: Mechanism of drug absorption and excretion. Passage of drugs in and out of the central nervous system. Annu Rev Pharmacol 2:109–128, 1962.CrossRefGoogle Scholar
  10. 10.
    Reese TS and Karnofsky J: Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:207–217, 1967.PubMedCrossRefGoogle Scholar
  11. 11.
    Long DM: Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg 32:127–144, 1970.PubMedCrossRefGoogle Scholar
  12. 12.
    Oldendorf WH: Blood-brain barrier permeability to drugs. Annu Rev Pharmacol 14:239–248, 1974.CrossRefGoogle Scholar
  13. 13.
    Vick NA, Khandekar JD, and Bigner DD: Chemotherapy of brain tumors (editorial). Arch Neurol 34:523–526, 1977.PubMedGoogle Scholar
  14. 14.
    Walker MD: Brain tumors. In: Cancer Medicine, JF Holland, and E Frei III (eds). Philadelphia: Lea & Febiger, 1973, p 1385–1407.Google Scholar
  15. 15.
    Walker MD, Alexander E Jr, Hunt WE, et al: Evaluation of mithramycin in the treatment of anaplastic gliomas. J Neurosurg 44:655–667, 1976.PubMedCrossRefGoogle Scholar
  16. 16.
    Walker MD and Hurwitz BS: BCNU l,3-bis(2-chloroethyl)-l-nitrosourea (NSC 409962) in the treatment of malignant brain tumor — a preliminary report. Cancer Chemother Rep 54:263–271, 1970.PubMedGoogle Scholar
  17. 17.
    Wilson CB, Boldrey EB, and Enot KJ: l,3-bis(2-chloroethyl)-l-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother Rep 54:273–281, 1970.PubMedGoogle Scholar
  18. 18.
    Walker MD, Alexander E Jr, Hunt WE, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333–343, 1978.PubMedCrossRefGoogle Scholar
  19. 19.
    Walker MD, Green SB, Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for malignant glioma after surgery. N Engl J Med 303:1323–1329, 1980.PubMedCrossRefGoogle Scholar
  20. 20.
    EORTC Brain Tumor Group: Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma — Final evaluation. Eur J Cancer 14:851–856, 1978.Google Scholar
  21. 21.
    Garrett MJ, Hughes HJ, and Freedman LS: A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma. Clin Oncol 4:71–76, 1978.PubMedGoogle Scholar
  22. 22.
    Reagan TJ, Bisel HF, Childs DS, et al: Controlled study of CCNU and radiation therapy in malignant astrocytoma. J Neurosurg 44:186–190, 1976.PubMedCrossRefGoogle Scholar
  23. 23.
    Weir B, Band P, Urtasun R, et al: Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas. J Neurosurg 45:129–134, 1976.PubMedCrossRefGoogle Scholar
  24. 24.
    Jellinger K, Kothbauer P, Vole D, et al: Combination chemotherapy (COMP protocol) and radiotherapy of anaplastic supratentorial gliomas. Acta Neurochir 51:1–13, 1979.CrossRefGoogle Scholar
  25. 25.
    Heiss W-D: Chemotherapy of malignant gliomas: Comparison of the effect of polychemo-and CCNU-therapy. Acta Neurochir 42:109–115, 1978.CrossRefGoogle Scholar
  26. 26.
    Shapiro WR and Young DF: Chemotherapy of malignant glioma with BCNU and vincristine. Neurology (Minneapolis) 24:380, 1974.Google Scholar
  27. 27.
    Seiler RW, Greiner RH, Zimmerman A, et al: Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas. J Neurosurg 48:861–865, 1978.PubMedCrossRefGoogle Scholar
  28. 28.
    Gehan EA and Walker MD: Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr 46:189–195, 1977.PubMedGoogle Scholar
  29. 29.
    Burger PC, Mahaley MS Jr, Dudka L, et al: The morphologic effects of radiation administered therapeutically for intracranial gliomas. Cancer 44:1256–1272, 1979.PubMedCrossRefGoogle Scholar
  30. 30.
    Cohen RJ, Wiernik PH, and Walker MD: Acute nonlymphocytic leukemia associated with nitrosourea chemotherapy: Report of two cases. Cancer Treat Rep 60:1257–1261, 1976.PubMedGoogle Scholar
  31. 31.
    Cushing H: Experiences with cerebellar astrocytomas — A critical review of 76 cases. Surg Gynecol Obstet 52:129–204, 1931.Google Scholar
  32. 32.
    Danoff BF, Kramer S, and Thompson N: The radiotherapeutic management of optic nerve gliomas in children. Int J Radiat Oncol Biol Phys 6:45–50, 1980.PubMedGoogle Scholar
  33. 33.
    Bloom HJG: Prospects for increasing survival in children with medulloblastoma: Present and future studies. Multidisciplin Aspects Br Turn Ther 1:245–259, 1979.Google Scholar
  34. 34.
    Evans AE, Anderson J, Chang C, et al: Adjuvant chemotherapy for medulloblastoma and ependymoma. Multidisciplin Aspects Br Turn Ther 1:219–222, 1979.Google Scholar
  35. 35.
    Rosenstock JG, Evans AE, and Schut L: Response to vincristine of recurrent brain tumors in children. J Neurosurg 45:135–140, 1976.PubMedCrossRefGoogle Scholar
  36. 36.
    Cangir A, Van Eys J, Berry DH, et al: Combination chemotherapy with MOPP in children with recurrent brain tumors. Med Ped Oncol 4:253–261, 1978.CrossRefGoogle Scholar
  37. 37.
    Thomas PR, Duffner PK, Cohen ME, et al: Multimodality therapy for medulloblastoma. Cancer 45:666–669, 1980.PubMedCrossRefGoogle Scholar
  38. 38.
    Shapiro WR: Chemotherapy of primary malignant brain tumors in children. Cancer 35:975, 1975.CrossRefGoogle Scholar
  39. 39.
    Zaunbauer F, Pichler E, and Fodor M: Experiences with radiotherapy and chemotherapy in the treatment of tumors involving the caudal brain stem. Mod Probl Paediatr 18:80–83, 1977.Google Scholar
  40. 40.
    Kumar ARV, Renaudin J, Wilson CB, et al: Procarbazine hydrochloride in the treatment of brain tumors — phase II study. J Neurosurg 40:365–371, 1974.CrossRefGoogle Scholar
  41. 41.
    Hoshino T, Barker M, and Wilson CB: The kinetics of cultured human glioma cells. Acta Neuropathol 32:235–244, 1975.Google Scholar
  42. 42.
    Hoshino T, Barker M, Wilson CB, et al: Cell kinetics of human gliomas. J Neurosurg 37:15–26, 1972.PubMedCrossRefGoogle Scholar
  43. 43.
    Walker MD, Goldware SI, Rockswold GL, et al: Regional infusion chemotherapy of head and neck in dogs. Fed Proc 29:681, 1970.Google Scholar
  44. 44.
    Levin VA, Kabra PM, and Freeman-Dove MA: Pharmacokinetics of intracarotid artery C-BCNU in the squirrel monkey. J Neurosurg 48:587–593, 1978.PubMedCrossRefGoogle Scholar
  45. 45.
    West CR, Avellanosa AM, Barua NR, et al: Phase II study on malignant gliomas of the brain treated with intra-arterial BCNU in combination with vincristine and procarbazine. Proceedings AACR 21:482, 1980.Google Scholar
  46. 46.
    Neuwelt E, Frenkel E, Bartnett P, et al: Methotrexate (MTX) pharmacokinetics after osmotic blood-brain barrier (BBB) disruption. Proceedings AACR 21:286, 1980.Google Scholar
  47. 47.
    Walker MD: Chemotherapy: Adjuvant to surgery and radiation therapy. Semin Oncol 2:69–72, 1975.PubMedGoogle Scholar
  48. 48.
    Walker MD: Nitrosoureas in central nervous system tumors. Cancer Chemother Reg 4:21–26, 1973.Google Scholar
  49. 49.
    Walker MD and Gehan E: An evaluation of 1,3 bis(2-chloroethyl)-l-nitrosourea (BCNU) alone and irradiation alone and in combination for the treatment of malignant glioma (abstract). Proc Am Assoc Cancer Res 15:67, 1972.Google Scholar
  50. 50.
    Takvorian R: Personal communication, 1980.Google Scholar
  51. 51.
    Kornblith PL and Szypko PE: Variations in response of human brain tumors to BCNU in vitro. J Neurosurg 48:580–586, 1978.PubMedCrossRefGoogle Scholar
  52. 52.
    Thomas DGT, Darling JL, Freshney RI, et al: In vitro chemosensitivity assay of human gliomas by scintillation autofluorography. In: Multidisciplinary Aspects of Brain Tumor Therapy P Paoletti, MD Walker, G Butte, et al (eds). Amsterdam: Elsevier North-Holland and Biomedical Press, 1979, p 19–34.Google Scholar
  53. 53.
    Rosenblum ML, Vasquez DA, Hoshino T, et al: Development of a clonogenic cell assay for human brain tumors. Cancer 41:2305–2314, 1978.PubMedCrossRefGoogle Scholar
  54. 54.
    Dakhil S, Ensminger W, Kindt G, et al: Implanted system for intraventricular drug infusion in central nervous system tumors. Cancer Treat Rep 65:401–411, 1981.PubMedGoogle Scholar
  55. 55.
    Oldfield EH, Dedrick RL, Chatterji DC, et al: Reduced systemic drug exposure by combining intracarotid chemotherapy with hemoperfusion of jugular drainage. Am Coll Surg 34:535–537, 1983.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1987

Authors and Affiliations

  • Paul L. Kornblith
  • Michael Walker

There are no affiliations available

Personalised recommendations